Free Trial

LifeStance Health Group (NASDAQ:LFST) Rating Increased to Strong-Buy at Zacks Research

LifeStance Health Group logo with Medical background

Key Points

  • LifeStance Health Group's rating has been upgraded from "hold" to "strong-buy" by Zacks Research, enhancing its market appeal.
  • The company reported a quarterly revenue of $345.31 million, marking a 10.6% year-over-year increase and exceeding analyst expectations.
  • Recent insider trading activities include significant stock sales, indicating a 20.05% decrease in ownership by Director Darren M. Black.
  • MarketBeat previews the top five stocks to own by November 1st.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a report issued on Tuesday,Zacks.com reports.

LFST has been the topic of a number of other reports. Wall Street Zen raised shares of LifeStance Health Group from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. UBS Group increased their price target on shares of LifeStance Health Group from $8.50 to $9.00 and gave the company a "buy" rating in a report on Friday, August 8th. BTIG Research assumed coverage on LifeStance Health Group in a research note on Friday, July 25th. They issued a "buy" rating and a $8.00 price objective for the company. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of LifeStance Health Group in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, LifeStance Health Group presently has a consensus rating of "Moderate Buy" and an average target price of $8.50.

Get Our Latest Analysis on LFST

LifeStance Health Group Stock Performance

NASDAQ LFST opened at $5.64 on Tuesday. The stock has a fifty day simple moving average of $5.18 and a 200-day simple moving average of $5.51. LifeStance Health Group has a twelve month low of $3.74 and a twelve month high of $8.61. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.19. The stock has a market cap of $2.19 billion, a PE ratio of -112.80 and a beta of 1.17.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. The business had revenue of $345.31 million for the quarter, compared to analysts' expectations of $345.05 million. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. The business's quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.06) earnings per share. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts anticipate that LifeStance Health Group will post -0.18 earnings per share for the current year.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, Director Darren M. Black sold 8,407,643 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the completion of the sale, the director directly owned 33,524,715 shares in the company, valued at $169,970,305.05. The trade was a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Summit Partners L. P sold 8,407,643 shares of the company's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.07, for a total value of $42,626,750.01. Following the completion of the sale, the insider directly owned 33,524,715 shares of the company's stock, valued at $169,970,305.05. The trade was a 20.05% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,407,643 shares of company stock valued at $103,466,750 over the last ninety days. Corporate insiders own 3.20% of the company's stock.

Institutional Trading of LifeStance Health Group

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Parcion Private Wealth LLC acquired a new stake in shares of LifeStance Health Group during the 1st quarter valued at approximately $15,670,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of LifeStance Health Group in the first quarter valued at approximately $7,932,000. Adage Capital Partners GP L.L.C. boosted its position in LifeStance Health Group by 43.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 230,000 shares of the company's stock worth $1,532,000 after acquiring an additional 70,000 shares during the period. Victory Capital Management Inc. grew its position in LifeStance Health Group by 2,599.0% in the 1st quarter. Victory Capital Management Inc. now owns 370,598 shares of the company's stock valued at $2,468,000 after buying an additional 356,867 shares in the last quarter. Finally, Nuveen LLC acquired a new position in LifeStance Health Group during the 1st quarter valued at about $6,928,000. Institutional investors own 85.50% of the company's stock.

LifeStance Health Group Company Profile

(Get Free Report)

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

Further Reading

Analyst Recommendations for LifeStance Health Group (NASDAQ:LFST)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in LifeStance Health Group Right Now?

Before you consider LifeStance Health Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.

While LifeStance Health Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.